In this issue:
BRCA-deficient metastatic prostate cancer
Healthcare costs in men with mCRPC
Olaparib + abiraterone in mCRPC
Darolutamide in non-mCRPC
Neoadjuvant cabazitaxel + abiraterone/leuprolide acetate in high-risk prostate cancer
Genomic classifier performance in intermediate-risk prostate cancer
NCCN guidelines for identifying pathogenic germline variants
AS for low-grade prostate cancer with a family history
Baseline PSA, cancer detection and prostate cancer death
Late puberty onset and highgrade prostate cancer in adulthood
Please login below to download this issue (PDF)